MaxCyte, Inc. (MXCT) Stock Score, Valuation & Financial Research
MaxCyte, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 23/100.
Quick answer for MXCT
MaxCyte, Inc. currently has a Wall Street Score of 23/100. The stored market price is $1.18. Its financial score is 29/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What MaxCyte, Inc. does
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical an
MXCT financial snapshot
- Wall Street Score:
- 23/100
- Current price:
- $1.18
- Market capitalization:
- $126.4M
- Revenue:
- $32.3M
- Net income:
- $-39.1M
- Free cash flow:
- $-36.2M
- Cash:
- $14.6M
- Total debt:
- $17.5M
- EPS:
- -0.42
- Financial score:
- 29/100
- Valuation score:
- 0/100
- Revenue score:
- 3/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $-36.2M, showing cash burn in the current stored period.
- The balance sheet shows $14.6M of cash versus $17.5M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 29/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research MXCT
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.